SARS-CoV-2 antibody prevalence in England following

Nature Communications 12, 905 DOI: 10.1038/s41467-021-21237-w

Citation Report

#	Article	IF	CITATIONS
1	Estimating the case fatality ratio for COVID-19 using a time-shifted distribution analysis. Epidemiology and Infection, 2021, 149, e197.	1.0	9
2	SARS-CoV-2 Testing of 11,884 Healthcare Workers at an Acute NHS Hospital Trust in England: A Retrospective Analysis. Frontiers in Medicine, 2021, 8, 636160.	1.2	13
5	Disparities of SARS-CoV-2 Nucleoprotein-Specific IgG in Healthcare Workers in East London, UK. Frontiers in Medicine, 2021, 8, 642723.	1.2	10
6	Resurgence of SARS-CoV-2: Detection by community viral surveillance. Science, 2021, 372, 990-995.	6.0	91
8	Testing at scale during the COVID-19 pandemic. Nature Reviews Genetics, 2021, 22, 415-426.	7.7	261
9	Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates. Scientific Reports, 2021, 11, 9748.	1.6	16
11	Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults. Lancet Regional Health - Europe, The, 2021, 4, 100098.	3.0	91
13	Population (Antibody) Testing for COVID-19—Technical Challenges, Application and Relevance, an English Perspective. Vaccines, 2021, 9, 550.	2.1	6
14	â€~Black African' identification and the COVIDâ€19 pandemic in Britain: A site for sociological, ethical and policy debate. Sociology of Health and Illness, 2021, , .	1.1	6
15	Racial disparities in COVID-19 pandemic cases, hospitalisations, and deaths: A systematic review and meta-analysis. Journal of Global Health, 2021, 11, 05015.	1.2	161
16	Community factors and excess mortality in first wave of the COVID-19 pandemic in England. Nature Communications, 2021, 12, 3755.	5.8	42
17	A Novel Spatiotemporal Method for Predicting Covid-19 Cases. WSEAS Transactions on Mathematics, 2021, 20, 300-311.	0.2	2
19	Weekly seroconversion rate of the mRNA-1273 SARS-CoV-2 vaccine in haemodialysis patients. Nephrology Dialysis Transplantation, 2021, 36, 1754-1755.	0.4	10
20	Association between SARS-CoV-2 exposure and antibody status among healthcare workers in two London hospitals: a cross-sectional study. Infection Prevention in Practice, 2021, 3, 100157.	0.6	3
21	Diabetes Increases Severe COVID-19 Outcomes Primarily in Younger Adults. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3364-e3368.	1.8	16
23	Impact of reduction of susceptibility to SARS-CoV-2 on epidemic dynamics in four early-seeded metropolitan regions. Scientific Reports, 2021, 11, 12213.	1.6	0
24	Large variation in anti-SARS-CoV-2 antibody prevalence among essential workers in Geneva, Switzerland. Nature Communications, 2021, 12, 3455.	5.8	30
25	Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. Cells, 2021, 10, 1412.	1.8	6

#	Article	IF	CITATIONS
26	SARS-CoV-2 infection and transmission in primary schools in England in June–December, 2020 (sKIDs): an active, prospective surveillance study. The Lancet Child and Adolescent Health, 2021, 5, 417-427.	2.7	78
27	Ethnic disparities in COVID-19: increased risk of infection or severe disease? – Authors' reply. Lancet, The, 2021, 398, 390.	6.3	12
28	Neutralizing Antibody Responses After SARS-CoV-2 Infection in End-Stage Kidney Disease and Protection Against Reinfection. Kidney International Reports, 2021, 6, 1799-1809.	0.4	13
30	Hospital admissions from care homes in England during the COVID-19 pandemic: a retrospective, cross-sectional analysis using linked administrative data. International Journal of Population Data Science, 2020, 5, 1663.	0.1	13
31	Seroprevalence of SARS oVâ€2 antibodies among rural healthcare workers. Journal of Medical Virology, 2021, 93, 6611-6618.	2.5	4
34	J <scp>une</scp> : open-source individual-based epidemiology simulation. Royal Society Open Science, 2021, 8, 210506.	1.1	14
37	Multiple sclerosis is not associated with an increased risk for severe COVID-19: a nationwide retrospective cross-sectional study from Germany. Neurological Research and Practice, 2021, 3, 42.	1.0	10
38	How reliable are COVID-19 burden estimates for India?. Lancet Infectious Diseases, The, 2021, 21, 1615-1617.	4.6	5
39	Patterns of within-host genetic diversity in SARS-CoV-2. ELife, 2021, 10, .	2.8	110
40	The Case for Mandating COVID-19 Vaccines for Health Care Workers. Annals of Internal Medicine, 2021, 174, 1305-1307.	2.0	21
41	Update on SARS-CoV-2 seroprevalence: regional and worldwide. Clinical Microbiology and Infection, 2021, 27, 1762-1771.	2.8	49
42	Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infectious Diseases, The, 2022, 22, 43-55.	4.6	573
43	COVID-19 and pregnancy: Lessons from 2020. Early Human Development, 2021, 162, 105460.	0.8	6
44	Neuroinflammation triggered by SARS-CoV-2 infection: syndromes and therapies. The Lancet Child and Adolescent Health, 2021, 5, 607-609.	2.7	1
45	Socioeconomic position and the COVID-19 care cascade from testing to mortality in Switzerland: a population-based analysis. Lancet Public Health, The, 2021, 6, e683-e691.	4.7	85
46	Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. Lancet Regional Health - Europe, The, 2021, 8, 100171.	3.0	70
47	Ethnic differences in risk of severe Covid-19: To what extent are they driven by exposure?. Journal of Public Health, 2021, , .	1.0	0
48	Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study). Vaccine, 2021, 39, 5376-5384.	1.7	9

#	Article	IF	CITATIONS
51	Seroprevalence of SARS-CoV-2–Specific Antibodies among Quarantined Close Contacts of COVID-19 Patients, Faroe Islands, 2020. Emerging Infectious Diseases, 2021, 27, 2795-2801.	2.0	3
52	Determinants of Pre-Vaccination Antibody Responses to SARS-CoV-2: A Population-Based Longitudinal Study (COVIDENCE UK). SSRN Electronic Journal, 0, , .	0.4	0
53	Acceptability, Usability, and Performance of Lateral Flow Immunoassay Tests for Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: REACT-2 Study of Self-Testing in Nonhealthcare Key Workers. Open Forum Infectious Diseases, 2021, 8, ofab496.	0.4	12
54	Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study. Scandinavian Journal of Public Health, 2022, 50, 124-135.	1.2	22
56	The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?. Nature Reviews Immunology, 2021, 21, 762-768.	10.6	80
57	Factors associated with COVID-19 Vaccine Hesitancy in Thai Seniors. Patient Preference and Adherence, 2021, Volume 15, 2389-2403.	0.8	40
59	Negative Association Between Smoking and Positive SARS-CoV-2 Testing: Results From a Swiss Outpatient Sample Population. Frontiers in Public Health, 2021, 9, 731981.	1.3	8
61	Quantifying the contribution of pathways of nosocomial acquisition of COVID-19 in English hospitals. International Journal of Epidemiology, 2022, 51, 393-403.	0.9	14
63	Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada. JAMA Network Open, 2021, 4, e2135975.	2.8	33
64	COVID-19 hospital activity and in-hospital mortality during the first and second waves of the pandemic in England: an observational study. Thorax, 2022, 77, 1113-1120.	2.7	34
65	Social inequalities and dynamics of the early COVID-19 epidemic: a prospective cohort study in France. BMJ Open, 2021, 11, e052888.	0.8	19
66	Serologic Survey of IgG Against SARS-CoV-2 Among Hospital Visitors Without a History of SARS-CoV-2 Infection in Tokyo, 2020–2021. Journal of Epidemiology, 2022, 32, 105-111.	1.1	19
67	Mental Health, Financial Hardship, and Social Connections Among Older Adults With Probable COVID-19 Infection: A Longitudinal Cohort Study. SSRN Electronic Journal, 0, , .	0.4	0
69	An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives. RSC Medicinal Chemistry, 2022, 13, 647-675.	1.7	3
70	SARS-CoV-2 sero-prevalence in the workforces of three large workplaces in South Wales: a sero-epidemiological study. BMC Public Health, 2022, 22, 162.	1.2	2
71	Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort. BMC Infectious Diseases, 2022, 22, 41.	1.3	31
72	Construction of SARS-CoV-2 virus-like particles in plant. Scientific Reports, 2022, 12, 1005.	1.6	26
73	Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: results from a seroprevalence study. Leukemia and Lymphoma, 2022, , 1-4.	0.6	1

#	Article	IF	CITATIONS
74	Helminths and COVID-19 susceptibility, disease progression, and vaccination efficacy. Trends in Parasitology, 2022, 38, 277-279.	1.5	10
75	Estimating SARS-CoV-2 seroprevalence in long-term care: a window of opportunity. The Lancet Healthy Longevity, 2022, 3, e2-e3.	2.0	2
76	Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico. Nature Communications, 2022, 13, 589.	5.8	29
77	Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians. Respiration, 2022, 101, 307-320.	1.2	5
80	COVID-19 serological survey-3 prior to second wave in Mumbai, India. Indian Journal of Community Medicine, 2022, 47, 61.	0.2	0
81	Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nature Communications, 2022, 13, 907.	5.8	94
82	Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults. JAMA Network Open, 2022, 5, e2146798.	2.8	20
83	Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK). BMC Medicine, 2022, 20, 87.	2.3	31
84	Commentary on training and education in medical statistics, in celebration of 40 years of statistics in medicine and 50 years of the <scp>MSc</scp> medical statistics at <scp>LSHTM</scp> . Statistics in Medicine, 2022, 41, 835-837.	0.8	1
86	Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan. Vaccines, 2022, 10, 312.	2.1	3
88	Age-specific rate of severe and critical SARS-CoV-2 infections estimated with multi-country seroprevalence studies. BMC Infectious Diseases, 2022, 22, 311.	1.3	43
90	Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21. Eurosurveillance, 2022, 27, .	3.9	13
92	Seroprevalence of SARSâ€CoVâ€2 among highâ€density communities and hyperâ€endemicity of COVIDâ€19 in Vietnam. Tropical Medicine and International Health, 2022, 27, 515-521.	1.0	5
93	Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population. Communications Medicine, 2022, 2, .	1.9	10
94	Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold. Journal of Theoretical Biology, 2022, 540, 111063.	0.8	75
96	The True Human Cost of the Novel Coronavirus 2019 (COVID-19) Pandemic. Indian Journal of Medical and Paediatric Oncology, 0, , .	0.1	0
97	Risk factors for excess all-cause mortality during the first wave of the COVID-19 pandemic in England: A retrospective cohort study of primary care data. PLoS ONE, 2021, 16, e0260381.	1.1	13
98	Household overcrowding and risk of SARS-CoV-2: analysis of the Virus Watch prospective community cohort study in England and Wales. Wellcome Open Research, 0, 6, 347.	0.9	10

#	Article	IF	CITATIONS
99	Estimating the strength of selection for new SARS-CoV-2 variants. Nature Communications, 2021, 12, 7239.	5.8	23
100	Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nature Communications, 2022, 13, 1957.	5.8	198
101	SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain) Blood Transfusion, 2022, , .	0.3	1
102	Critical weaknesses in shielding strategies for COVID-19. PLOS Global Public Health, 2022, 2, e0000298.	0.5	9
103	Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort–EPICOV. PLoS ONE, 2022, 17, e0267725.	1.1	16
104	Risk factors associated with SARS-CoV-2 infection in a multiethnic cohort of United Kingdom healthcare workers (UK-REACH): A cross-sectional analysis. PLoS Medicine, 2022, 19, e1004015.	3.9	28
109	COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data. PLoS ONE, 2022, 17, e0266945.	1.1	6
110	COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records. The Lancet Digital Health, 2022, 4, e542-e557.	5.9	40
111	Mental health, financial, and social outcomes among older adults with probable COVID-19 infection: A longitudinal cohort study. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	12
112	Effective high-throughput RT-qPCR screening for SARS-CoV-2 infections in children. Nature Communications, 2022, 13, .	5.8	14
113	Burden of SARS-CoV-2 infection in healthcare workers during second wave in England and impact of vaccines: prospective multicentre cohort study (SIREN) and mathematical model. BMJ, The, 0, , e070379.	3.0	14
114	Indicators of recent COVID-19 infection status: findings from a large occupational cohort of staff and postgraduate research students from a UK university. BMC Public Health, 2022, 22, .	1.2	0
115	Refining epidemiological forecasts with simple scoring rules. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2022, 380, .	1.6	3
117	Validity of Self-testing at Home With Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Detection by Lateral Flow Immunoassay. Clinical Infectious Diseases, 2023, 76, 658-666.	2.9	5
118	The challenges of data in future pandemics. Epidemics, 2022, 40, 100612.	1.5	12
119	A prospective study of risk factors associated with seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a large UK teaching hospital. Journal of Infection, 2022, 85, 557-564.	1.7	7
120	Tracking the incidence and risk factors for SARS-CoV-2 infection using historical maternal booking serum samples. PLoS ONE, 2022, 17, e0273966.	1.1	1
122	Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK). Lancet Regional Health - Europe, The, 2022, 22, 100501.	3.0	9

#	Article	IF	CITATIONS
123	Sources of SARS-CoV-2 transmission in Jordan: Self-reported approach. Informatics in Medicine Unlocked, 2022, 32, 101075.	1.9	1
124	Determinants of Antibody Responses to SARS-CoV-2 Vaccines: Population-Based Longitudinal Study (COVIDENCE UK). Vaccines, 2022, 10, 1601.	2.1	20
125	Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. Nature Communications, 2022, 13, .	5.8	42
126	Socio-economic determinants of SARS-CoV-2 infection: Results from a population-based cross-sectional serosurvey in Geneva, Switzerland. Frontiers in Public Health, 0, 10, .	1.3	3
128	Prevalence and Factors Associated with Caregivers' Hesitancy in Immunizing Dependent Older Adults with COVID-19 Vaccines: A Cross-Sectional Survey. Vaccines, 2022, 10, 1748.	2.1	1
129	Differential Patterns by Area-Level Social Determinants of Health in Coronavirus Disease 2019 (COVID-19)–Related Mortality and Non–COVID-19 Mortality: A Population-Based Study of 11.8 Million People in Ontario, Canada. Clinical Infectious Diseases, 2023, 76, 1110-1120.	2.9	13
130	Patterns of reported infection and reinfection of SARS-CoV-2 in England. Journal of Theoretical Biology, 2023, 556, 111299.	0.8	7
131	Higher Infection Risk among Health Care Workers and Lower Risk among Smokers Persistent across SARS-CoV-2 Waves—Longitudinal Results from the Population-Based TiKoCo Seroprevalence Study. International Journal of Environmental Research and Public Health, 2022, 19, 16996.	1.2	4
132	Steven Riley's discussion contribution to papers in Session 1 of the Royal Statistical Society's Special Topic Meeting on COVIDâ€19 transmission: 9 June 2021. Journal of the Royal Statistical Society Series A: Statistics in Society, 0, , .	0.6	0
133	Rapid rise in COVID-19 among young people in England – learning for the future. Public Health, 2023, 218, 136-138.	1.4	0
135	SARS-CoV-2 seroprevalence in children worldwide: a systematic review and meta-analysis. EClinicalMedicine, 2023, 56, 101786.	3.2	18
136	Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region. IScience, 2023, 26, 105928.	1.9	5
137	Factors associated with receipt of COVID-19 vaccination and SARS-CoV-2 seropositivity among healthcare workers in Albania (February 2021–June 2022): secondary analysis of a prospective cohort study. Lancet Regional Health - Europe, The, 2023, 27, 100584.	3.0	6
138	A Systematic Literature Review of the Impact of COVID-19 on the Health of LGBTQIA+ Older Adults: Identification of Risk and Protective Health Factors and Development of a Model of Health and Disease. Journal of Homosexuality, 2024, 71, 1297-1331.	1.3	4
140	Ethnic inequalities in COVID-19 infection, hospitalisation, intensive care admission, and death: a global systematic review and meta-analysis of over 200 million study participants. EClinicalMedicine, 2023, 57, 101877.	3.2	20
141	Population Monitoring of SARS-CoV-2 Infections via Random Sampling During the COVID-19 Pandemic. American Journal of Public Health, 2023, 113, 514-516.	1.5	2
142	Clinical sensitivity and specificity of a high-throughput microfluidic nano-immunoassay combined with capillary blood microsampling for the identification of anti-SARS-CoV-2 Spike IgG serostatus. PLoS ONE, 2023, 18, e0283149.	1.1	1
143	Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: aÂcross-sectional analysis. EClinicalMedicine, 2023, 58, 101926.	3.2	6

#	Article	IF	CITATIONS
144	Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants. Communications Biology, 2023, 6, .	2.0	0
145	A systematic outbreak investigation of SARS-CoV-2 transmission clusters in a tertiary academic care center. Antimicrobial Resistance and Infection Control, 2023, 12, .	1.5	1